The Pennant Group: The Pros Of Investing Continue To Outweigh The Cons

Summary I am maintaining my Buy rating on The Pennant Group driven by robust fundamentals and +200% stock appreciation since April 2023. PNTG delivered 36% revenue growth in 2025 and guides for 25% growth in 2026, with adjusted EPS of $1.34–$1.41 and EBITDA of $94.4–$98M. Strategic acquisitions, disciplined growth, and a culture of operational excellence underpin PNTG’s expansion in home health, hospice, and senior living. While scaling introduces operational and reputational risks, PNTG’s strong execution and industry positioning support continued upside potential. Looking for option income ideas that focus on capital preservation? I offer this and much more at my exclusive investing ideas service, Haggerston BioHealth. Learn More » JARAMA/iStock via Getty Images Investment Overview I gave the stock of The Pennant Group ( PNTG ) a Buy rating when I last covered the company for Seeking Alpha in April 2023, and am pleased to report that nearly three-and-a-half years later, it has risen in This article was written by Edmund Ingham 15.18K Followers Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PNTG over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.